International Flavors & Fragrances Inc. (IFF) Cash Flow Statement

The gap between net income and operating cash flow is substantial, particularly in quarters with large impairments or one-time charges, such as 2025Q1 when net income was -$1.0B but OCF was positive $127M. This indicates that reported earnings understate the company's cash-generating ability, but also that the quality of earnings is distorted by non-cash charges like D&A and impairments. Investors should focus on cash flow as a more reliable indicator of underlying performance, but the volatility in OCF/NI across quarters (ranging from -8.00 to 10.26) suggests inconsistent earnings quality.

The FCF trajectory shows improvement from the trough in early 2025, but it is not yet stable. The latest quarter's FCF of $284M is the highest in the ten-quarter period, yet it follows a quarter with only $92M, indicating volatility. Compared to net income, FCF is consistently higher, but the margin remains below the peer average of around 13-15%, suggesting that IFF is still deleveraging and not yet generating excess cash. The negative FCF in 2025Q1 and 2024Q1 highlights the cyclicality and the impact of working capital swings.

The CapEx/Revenue ratio is relatively low compared to typical chemical companies, but it spiked in 2025Q4 and 2026Q1, possibly reflecting investments in high-growth areas like Health & Biosciences. The low ratio in 2025Q3 (0.9%) suggests a temporary pause in spending, which may indicate management's focus on cash preservation. Given the company's divestiture of Pharma Solutions, the capital base is likely to shrink, but the need for maintenance CapEx in the remaining segments remains. Investors should monitor whether CapEx is sufficient to sustain the moat in flavor and fragrance innovation.

The negative working capital changes in most quarters suggest that IFF is consuming cash to fund inventory build-ups or receivables, which is consistent with the revenue decline and potential destocking by customers. The positive changes in 2024Q4 and 2025Q4 provided a temporary boost to cash flow, but the overall trend is negative, with cumulative working capital outflow over the ten quarters. This may indicate inefficiencies in collections or inventory management, which could pressure cash flow if not addressed. The company's ability to manage working capital will be critical to improving FCF stability.

The company has maintained its dividend despite negative net income in some quarters, which is a positive signal for income investors, but it consumes a significant portion of FCF. Buybacks have been negligible, and the large acquisition outflow in 2025Q2 ($2.7B) reflects the divestiture of Pharma Solutions, which generated cash. The net cash from acquisitions in 2026Q1 ($198M) suggests continued portfolio pruning. Overall, capital deployment appears aimed at reducing debt and simplifying the portfolio, but the dividend sustainability depends on FCF generation, which remains volatile.

The cumulative gap between net income and operating cash flow is substantial, driven by large D&A charges (averaging ~$240M per quarter) and impairment charges in 2025Q1. This suggests that the company's cash-generating ability is stronger than GAAP earnings suggest, but it also raises questions about the sustainability of these non-cash charges. The divergence is typical for companies with significant acquisition-related amortization, but the magnitude here is notable. Investors should use cash flow metrics to assess the company's true earning power, but the negative cumulative net income indicates that the company is not yet profitable on a GAAP basis.